Clinical Trial Update: An Observational Study on the Sorin Group New Brady Leads XFine and Beflex

View source ↗

Summary

A completed observational study evaluating Sorin Group's new bradycardia pacing leads XFine and Beflex for pacing lead implantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrioventricular Block
• Bradycardia

Snippet

Sponsor: LivaNova | Conditions: Pacing Leads Implantation | Status: COMPLETED